Literature DB >> 9728473

Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991-1993).

C A Wood1, A S Moore, J M Gliatto, L A Ablin, R J Berg, W M Rand.   

Abstract

A retrospective analysis was performed on the case records of 32 dogs with Stage I or II splenic hemangiosarcoma that were treated by splenectomy alone and that survived the seven-day postoperative period. Median survival time for these 32 cases was 86 days (mean, 116 days; range, 14 to 470 days), and the one-year survival rate was estimated to be 6.25%. Survival was not influenced by signalment, presenting signs, stage of disease, or clinicopathological findings. The data provides a basis from which to evaluate adjuvant chemotherapy for splenic hemangiosarcoma that is confined to the spleen macroscopically.

Entities:  

Mesh:

Year:  1998        PMID: 9728473     DOI: 10.5326/15473317-34-5-417

Source DB:  PubMed          Journal:  J Am Anim Hosp Assoc        ISSN: 0587-2871            Impact factor:   1.023


  22 in total

1.  Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.

Authors:  S Anthony Kahn; Christine M Mullin; Louis-Philippe de Lorimier; Kristine E Burgess; Rebecca E Risbon; Rogers M Fred; Kenneth Drobatz; Craig A Clifford
Journal:  Can Vet J       Date:  2013-03       Impact factor: 1.008

2.  Laparoscopic-assisted extirpation of falciform ligament hemangiosarcoma in a dog.

Authors:  Katie Hoddinott; Ameet Singh; Evan C Crawford; Elizabeth V Guieu; Danielle Richardson
Journal:  Can Vet J       Date:  2015-04       Impact factor: 1.008

3.  Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines.

Authors:  Mami Adachi; Yuki Hoshino; Yusuke Izumi; Hiroki Sakai; Satoshi Takagi
Journal:  Can J Vet Res       Date:  2016-07       Impact factor: 1.310

4.  Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005-2014).

Authors:  Karen Batschinski; Alessandra Nobre; Ernesto Vargas-Mendez; Marcello V Tedardi; Juliana Cirillo; Greice Cestari; Rodrigo Ubukata; Maria Lucia Z Dagli
Journal:  Can Vet J       Date:  2018-09       Impact factor: 1.008

5.  Outcome and prognostic factors for dogs with a histological diagnosis of splenic hematoma following splenectomy: 35 cases (2001-2013).

Authors:  Steve G Patten; Sarah E Boston; Gabrielle J Monteith
Journal:  Can Vet J       Date:  2016-08       Impact factor: 1.008

6.  Anticancer effects of resveratrol in canine hemangiosarcoma cell lines.

Authors:  A Carlson; K S Alderete; M K O Grant; D M Seelig; L C Sharkey; B N M Zordoky
Journal:  Vet Comp Oncol       Date:  2017-12-13       Impact factor: 2.613

7.  Factors associated with long-term survival in dogs undergoing liver lobectomy as treatment for liver tumors.

Authors:  Jessica R Kinsey; Stephen D Gilson; Joe Hauptman; Steve J Mehler; Lauren R May
Journal:  Can Vet J       Date:  2015-06       Impact factor: 1.008

8.  Development and validation of a multivariable model and online decision-support calculator to aid in preoperative discrimination of benign from malignant splenic masses in dogs.

Authors:  Kristine E Burgess; Lori Lyn Price; Ryan King; Manlik Kwong; Eliza Grant; Katherine A Olson; Jeremiah A Lyons; Nicholas A Robinson; Kristin M Wendelburg; John Berg
Journal:  J Am Vet Med Assoc       Date:  2021-06-15       Impact factor: 1.936

9.  Retrospective evaluation of thrombocytopenia and tumor stage as prognostic indicators in dogs with splenic hemangiosarcoma.

Authors:  Alison R Masyr; Aaron K Rendahl; Amber L Winter; Antonella Borgatti; Jaime F Modiano
Journal:  J Am Vet Med Assoc       Date:  2021-03-15       Impact factor: 1.936

10.  Single agent polysaccharopeptide delays metastases and improves survival in naturally occurring hemangiosarcoma.

Authors:  Dorothy Cimino Brown; Jennifer Reetz
Journal:  Evid Based Complement Alternat Med       Date:  2012-09-05       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.